The FDA is moving to ban compounded versions of semaglutide and tirzepatide after Novo Nordisk and Eli Lilly restored supply of Ozempic, Wegovy, and Mounjaro. The regulatory shift ends a temporary US market anomaly where pharmacies could legally produce patented drug copies during shortages, a practice restricted or prohibited across Europe, Canada, and most developed markets.
TomorrowsRx and competitors Hims & Hers, Ro, and Henry Meds built subscription models around compounded GLP-1 drugs priced at $200-$400 monthly, undercutting brand prices of $900-$1,300. US compounding rules allowed this only during shortage periods. Novo Nordisk reported restored Wegovy supply in Q4 2025. Eli Lilly increased Mounjaro capacity 50% in 2025.
The business model has no international equivalent. European regulators prohibit compounding patented drugs regardless of supply status. Canada's framework restricts compounding to patient-specific needs, blocking commercial-scale operations. Australia requires case-by-case approvals. The US shortage exemption created a temporary arbitrage between patent protections and access pricing.
Hims & Hers stock dropped 17% in January 2026 on compounding ban concerns. TomorrowsRx faces similar pressure without a post-compounding revenue model. Three options remain: negotiate wholesale agreements with manufacturers at compressed margins, shift to other shortage-designated drugs with lower demand, or exit weight management entirely.
Global GLP-1 pricing varies sharply. Wegovy costs $92 monthly in Denmark with insurance, $270 in Germany, and $1,349 in the US without coverage. The compounding window temporarily narrowed this gap for US telehealth patients. Most international markets never offered comparable low-cost access.
The FDA has not set a formal timeline but indicated action within 2026. Companies have months to restructure. The crackdown prioritizes patent enforcement and safety oversight over the telehealth access model that briefly disrupted US weight-loss treatment pricing. For platforms built on compounding economics, regulatory risk has shifted from theoretical to immediate.
Sources:
1 Globe Newswire, "TomorrowsRx Telehealth Service Outlines Prescription Access for Compounded Semaglutide and Advanced " (January 28, 2026)